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COMMENTARY
Syncope Risk Stratiﬁcation in the ED:
Directions for Future Research
S
yncope is a common and vexing chief complaint
in emergency departments (EDs). In the United
States, there are 740,000 annual events of syn-
cope that lead to an ED visit, resulting in 250,000 admis-
sions1 and $2.4 billion in yearly hospital costs.2 Because
syncope may be the result of a dangerous condition that
has not been revealed by the ED evaluation, patients
are often admitted for diagnostic purposes. However,
admission is associated with low diagnostic and thera-
peutic yield,3,4 and there is no evidence that current
practice patterns improve quality-of-life or long-term
survival.5 As a result, there is international interest in
improving diagnostic algorithms for syncope, and multi-
ple risk-stratiﬁcation tools have been published that
attempt to identify patients who may be safely dis-
charged.6–12
The San Francisco Syncope Rule (SFSR) is perhaps
the best known example of these decision aides.9 The
SFSR was rigorously derived and identiﬁed ﬁve predic-
tors for adverse outcomes after syncope, and absence
of these factors was associated with very low risk. Vali-
dation by the original investigators reported high sensi-
tivity (98%) and speciﬁcity (56%).13
In this issue of AEM, Tan et al.14 assess the perfor-
mance of the SFSR in a Singaporean cohort of 1,250
patients who presented to an ED with syncope. The
overall sensitivity and speciﬁcity for a 7-day adverse
outcome were 94 and 51%, respectively. In a post hoc
analysis that excluded patients who had dangerous con-
dition identiﬁed during the ED evaluation, the SFSR
also exhibited a sensitivity of 94%. Emergency physi-
cians admitted 100% of patients who experienced a
serious event; strict application of the SFSR would have
reduced admissions by 11% at the cost of discharging
6% of patients who experienced a serious outcome. The
authors conclude that the SFSR should supplement,
rather than replace, clinical judgment.14
These ﬁndings are consistent with a large and grow-
ing literature in other settings. Validation studies in
external cohorts suggested less optimistic performance
of the SFSR than originally reported,15–20 and this over-
all conclusion was conﬁrmed by a meta-analysis of 18
studies.21 Performance differences from the original
reports may be in part due to differing eligibility criteria
and deﬁnitions of the SFSR predictors, such as what
constitutes an “abnormal” electrocardiogram, but it is
unlikely that this body of research can be entirely dis-
counted on methodologic grounds.
As researchers who have studied ED syncope risk
stratiﬁcation, we believe that additional validation stud-
ies of the SFSR are unlikely to add much incremental
value. None of the published decision aides, including
the SFSR, are ready for routine clinical use, but they do
provide an important foundation for subsequent work.
There are excellent articles on the general approach to
developing and validating clinical prediction tools22,23;
here we offer a set of observations and suggestions spe-
ciﬁc to syncope risk stratiﬁcation. We acknowledge that
risk stratiﬁcation is just one facet of clinical manage-
ment, and this editorial does not address other contro-
versies about the workup of syncope, e.g., optimal
duration of hospital and outpatient cardiac monitoring,
utility of speciﬁc tests, and the protocols for observation
and syncope specialty units.
PRINCIPLES FOR FUTURE RISK-STRATIFICATION
RESEARCH
1. Standardized data reporting. A major challenge to
synthesizing existing studies is the marked variation
in deﬁning study eligibility, outcomes, and predic-
tors.21 For example, the criteria for “syncope” have
differed among published studies. To address the
problem, a multispecialty international expert panel
recently published reporting guidelines for syncope
risk-stratiﬁcation research.24 Adherence to these
guidelines should facilitate future literature review,
data pooling, and meta-analysis.
2. Exclude patients with “obvious” serious conditions.
Virtually all published risk-stratiﬁcation studies have
included patients who had a serious condition iden-
tiﬁed during the ED evaluation. From a clinical per-
spective, risk stratiﬁcation is unnecessary if a
dangerous diagnosis is already known. Inclusion of
such patients in risk-stratiﬁcation studies also biases
results toward the identiﬁcation of “obvious” prob-
lems. For example, we found that a low hematocrit
was predictive of serious outcomes in a managed
care cohort of older adults with syncope; however,
when patients with obvious gastrointestinal bleed
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were excluded, hematocrit was no longer associated
with adverse events.25
3. Use clinically coherent outcome categories. Clini-
cians desire a prediction instrument that excludes
“omni-badness,” i.e., any dangerous condition that
might be associated with syncope. Unfortunately,
the factors that predict cardiac arrhythmia, pulmo-
nary embolism, vertebrobasilar stroke, and occult
gastrointestinal bleed are likely to be very different.
Lumping together such disparate conditions creates
the illusion of completeness; in reality, the resulting
decision aid will be best at predicting the most com-
mon outcome observed in the study cohort and do a
poor job at predicting less common outcomes.
Although it may be clinically unwieldy, focusing on
coherent outcome classes may result in more valid
instruments. For example, there are no existing deci-
sion aids to exclude “omni-badness” in patients who
complain of chest pain; however, there are well-vali-
dated risk-stratiﬁcation scores for the speciﬁc diag-
noses of coronary ischemia and pulmonary
embolism.
4. Use a uniform outcome time frame. Prior investiga-
tors have measured outcomes ranging from 7 days
to 1 year after the ED index visit. Using short time
frames will detect syncope-related outcomes with
high speciﬁcity at the cost of sensitivity; conversely,
long time frames (e.g., 1 year) may not be relevant
for deciding whether to acutely admit a patient and
will also capture events that are unrelated to the ini-
tial syncope episode. Although the determination of
a clinically relevant outcome time frame is admit-
tedly arbitrary, an international expert panel sug-
gested the measurement of 30-day outcomes.24
5. Enroll large sample sizes. A major challenge to
researchers is the relatively low rate of dangerous
events after an unrevealing ED evaluation (~7%).25
Prior derivation studies included between 30 to 104
patients with serious outcomes, and small sample
sizes may contribute to unstable models that do not
generalize to other settings. External funding and
data pooling from multiple cohorts are likely needed
to overcome sample size challenges.
6. Evaluate the role of new tests. The approach to eval-
uating syncope relies on the triad of careful history
taking, a comprehensive physical examination, and a
12-lead electrocardiogram. The published literature
has been static in the sense that measured predic-
tors, which match this traditional approach to syn-
cope evaluation, have not changed appreciably in
the past 20 years. However, newer tests such as
high-sensitivity troponins, natriuretic peptides, and
bedside cardiac ultrasound performed by emergency
physicians may provide objective and prognostic
information about structural heart abnormalities
which may not have been available in the past. We
encourage the evaluation of such technologies in
future research.
7. Generate continuous, rather than binary, assess-
ments of risk. The paradigm of identifying “no-risk”
patients has tremendous appeal for emergency phy-
sicians, and this approach has been successful in
the development of clinical decision aids to exclude
some types of traumatic injuries. For syncope, no-
risk patients are likely to be young and healthy
individuals who have a presumptive vasovagal
mechanism; identiﬁcation of such patients is unlikely
to improve practice since they are almost never
admitted in the ﬁrst place. However, we are highly
skeptical that a no-risk subgroup can be reliably
identiﬁed in patients for whom there is currently
uncertainty about clinical management—older adults
who have a nonzero risk of serious outcomes even
in the absence of syncope. Furthermore, a binary
approach provides no additional information about
patients who are categorized as “non–no risk.”
Finally, disposition after syncope is no longer a bin-
ary decision to admit versus discharge, as observa-
tion units may provide a safe alternative for the
evaluation of intermediate-risk patients.26 We
believe that information about risk categories (e.g.,
high, intermediate, low), rather than a binary
assessment, will provide actionable information to
clinicians.
8. Compare decision aids to existing physician perfor-
mance. Given the difﬁculty of identifying the no-risk
patient, can a risk stratiﬁcation instrument ever be
useful? We believe that a decision aid that, on aver-
age, outperforms existing physician practice would
be beneﬁcial. That is, a decision aid does not need to
be perfect to be helpful. The ideal situation would be
a decision aid that has equivalent or better sensitiv-
ity, and better speciﬁcity, than provider perfor-
mance. In reality, there are likely to be tradeoffs
between sensitivity and speciﬁcity, e.g., a decision
aid that substantially reduces admissions at the cost
of a few missed outcomes. To complicate things fur-
ther, decision aid performance will likely be context
dependent and may safely reduce admissions in
some settings but not in others.20 Despite these chal-
lenges, comparison of a new instrument to existing
performance is essential to assess the potential bene-
ﬁt of the decision aid. Cost-effectiveness analyses
may be helpful to assess decision aids that improve
speciﬁcity at the cost of sensitivity.
9. Obtain external funding. Although this is an obvious
suggestion to conduct high-quality research, obtain-
ing support for syncope studies is challenging. Syn-
cope is an orphan syndrome that does not “belong”
to any single disease- or population-speciﬁc funding
agency. In addition, development of a clinical deci-
sion aid may straddle the boundaries of clinical and
health services research, which may further compli-
cate the identiﬁcation of an appropriate sponsor.
Creating study teams with complementing expertise
(e.g., emergency medicine, cardiology, neurology,
geriatrics, internal medicine, health services
research) and cultivating relationships with program
ofﬁcers at multiple agencies may improve the chance
of funding success.
CREATING A SYNCOPE RESEARCH COMMUNITY
Despite the considerable international interest in improv-
ing the management of syncope,27–29 research has been
fragmented across different specialties, countries, and
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medical centers. We brieﬂy describe a grass roots effort
by syncope researchers to develop an international
forum for idea exchange and study collaboration.
The ﬁrst international workshop on ED syncope risk
stratiﬁcation is being organized by clinical researchers
at the University of Milan and will be held in Gargnano,
Italy, in September 2013. This forum will include
researchers who have made a substantial contribution
to syncope risk stratiﬁcation in the ED. Sessions will
summarize the current state of the risk-stratiﬁcation
literature, identify a consensus on “best practices”
supported by existing data, identify the areas of uncer-
tainty where more studies are needed, and develop an
infrastructure for future international multicenter stud-
ies. We believe that this meeting will build on and
improve the principles for future syncope risk-stratiﬁca-
tion research described in this editorial.
SUMMARY
Despite decades of research, there continues to be
uncertainty about how best to risk stratify and evaluate
patients who present to an ED with syncope. Existing
risk-stratiﬁcation tools, including the SFSR, are not
ready for routine clinical use, but they do provide
important lessons. We suggest nine principles for future
risk stratiﬁcation research and are hopeful that increas-
ing international interest and collaboration on this topic
will result in novel and improved algorithms of care.
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